Pharma sees more post-M&A rebrands than other industries—and it does them better, too

Fiercepharma | June 03, 2020

Pharma sees more post-M&A rebrands than other industries—and it does them better, too
To rebrand or not? It’s a big question for pharma companies before and after acquisitions—and one answered with "yes" more often than in other industries. Pharma, in fact, was the most prolific rebrander in Brand Finance’s recent research assessing the value of rebrands across 25 industries. It's also one of the most successful, with rebrands in pharma generating average returns of 13.8%, according to Brand Finance calculations. The main reason? Most acquired pharma brands are weaker than the acquiring ones, the study found. Pharma rebranded 31% of the companies acquired in deals during the five-year study period beginning Jan. 2014 and ending Dec. 2018. That figure was just ahead of the healthcare (30%), telecom (29%) and oil and gas (25%) industries. The study assessed all deals valued at $500 million or more.

Spotlight

Wearable technology is actively being used by healthcare providers to enhance the patient/clinician engagement process and improve healthcare outcomes for patients and sufferers of chronic diseases. Today we're exploring how wearable technology is transforming digital health.

Related News

Levine Leichtman Capital Partners Portfolio Company Capsa Healthcare Acquires RoboPharma

Capsa Healthcare | August 14, 2020

Capsa Healthcare ("Capsa"), a portfolio company of Levine Leichtman Capital Partners ("LLCP"), announced today that it has acquired NewRobo Development B.V. and subsidiaries (collectively, "RoboPharma"). RoboPharma, based in Waalwijk, Netherlands, creates and implements pharmacy automation solutions for some of the largest pharmacies in Europe. Capsa is a leading provider of innovative, highly engineered workflow products that increase efficiency and reduce costs, enhance medication security, and tighten inventory control across healthcare settings worldwide. Capsa's core offerings include mobile workstations, medication management solutions, and pharmacy automation products sold to over 3,000 end customers, including leading health systems, senior care communities, and major retail and institutional pharmacies. Capsa was founded in 1958 and is headquartered in Portland, Oregon with additional production facilities in Columbus, Ohio and Agua Prieta, Mexico.

Read More

Recursion Acquires Vium Strengthening Its Attempts to Industrialize Drug Discovery

Recursion, Vium | July 29, 2020

Recursion, a digital biology company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium company. Vium’s platform combines computer vision, machine learning and sensor technologies to non-invasively collect and derive insights from digital biomarkers in preclinical in vivo research. Recursion’s acquisition of Vium signals continued and rapid integration of advanced technologies to grow its drug discovery pipeline of over 30 programs along with programs developed jointly with large pharmaceutical partners. “Technology is set to change the pace, scale and cost of drug discovery over the coming decades. At Recursion, we are building a vast machine to rapidly discover drugs through the integration of technology at every step in the process,” said Chris Gibson, Ph.D., co-founder and CEO of Recursion. “Bringing the fantastic team at Vium in-house will enable us to build on our core technology and vision, augmenting our huge in vitro datasets with large, complementary in vivo datasets, and advancing our mission to decode biology to radically improve patient lives.”

Read More

PHARMA TECH

Tranquilmoney Releases PharmTracker for Independent Pharmacies, Small and Medium Pharmacy Chains

Tranquilmoney | December 28, 2020

Tranquilmoney, Inc., an organization that oversaw drug store outsider case compromise for Costco Pharmacy for more than 20 years, has delivered an electronic adaptation of its product. Any drug store would now be able to join to PharmTrackerTM and begin utilizing the framework to handle their cases. Tranquilmoney has overseen over $1 billion per year in drug store receivables compromise with 100% compromise and 99.9% assortments. Industry guidelines of assortment are about 92.5%. Dr. Karun Philip, Chairman and CEO, says "Drug store claims are moderately little with a normal of $40 from the protection plans. More than 20 years, we built up a framework that consolidated Artificial Intelligence, enormous information stockrooms, and area specialists, that in blend permit us to coordinate each installment to its relating guarantee. Thusly, all non-installments are recognized, and an underpayment of even one penny is identified and can be rebilled." PharmTrackerTM can be utilized as a self-administration programming on the web or as a reevaluated administration. Utilizing Tranquiilmoney's framework will help a Pharmacy gather as much as 99.9% from protection, more than the business standard of about 92.5%. Tranquilmoney expenses start at 45 pennies for every case for at least 3000 cases for each month going down to 2 pennies a case for bigger volumes. Here is the finished value list.

Read More

Spotlight

Wearable technology is actively being used by healthcare providers to enhance the patient/clinician engagement process and improve healthcare outcomes for patients and sufferers of chronic diseases. Today we're exploring how wearable technology is transforming digital health.